The Stroke Association response to "Further analysis from the ATHENA Study showed that Multaq (dronedarone) reduced the risk of stroke in patients with atrial fibrillation”

Dr Peter Coleman, Deputy Director of Research at The Stroke Association comments:

“Atrial Fibrillation is an important risk factor for stroke and is responsible for around 15% of all strokes.  The use of an anti-arrhythmic drug, such as dronedarone opens up exciting possibilities, highlighted by this new analysis.  It is very encouraging that dronedarone appears to be effective in reducing stroke risk in patients with Atrial Fibrillation.”

ENDS

For further information please contact The Stroke Association Press Office on 020 7566 1500 or email the Press Office

Notes to editor

1.  The Stroke Association is the only UK charity solely concerned with combating stroke in people of all ages.  The charity funds research into prevention, treatment, better methods of rehabilitation and helps stroke patients and their families directly through its community services which include communications support, family and carer support services, information services, welfare grants, publications and leaflets.  The Stroke Association also campaigns, educates and informs to increase knowledge of stroke at all levels of society acting as a voice for everyone affected by stroke.

2.  A stroke is a brain attack which causes brain damage.  A stroke can be diagnosed by using FAST – Facial weakness, Arm weakness, Speech problems, Time to call 999.  If any of these symptoms are present call an ambulance straight away. 

3.  The Stroke Helpline provides information on stroke to the general public and is open from 9am – 5pm Monday to Friday on 0845 3033 100

back to top|